• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

This comprehensive report is designed to present a state-of-the-art view of chemotherapy approaches to the treatment of cancer and an assessment of the critical parameters of drug discovery and development that may lead to the introduction of new oncology drugs with great therapeutic and market potential over the next decade. The oncology market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade. Currently, there are 25 million people afflicted with cancer worldwide, and the World Health Organization (WHO) predicts that cancer rates may increase by 50% from 10 million cases in 2000 to 15 million cases in 2015. Moreover, the Association for International Cancer Research (AICR) estimates that by 2020, there will be 10 million deaths from cancer. Even in developed nations, approximately 50% of patients diagnosed with cancer will eventually die of this disease. The challenges are great, but the world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcome.

In this report, Chemotherapy Market Insights, 2006-2016: A Critical Analysis of CancerResearch, Treatments, Pipelines, and Commercial Opportunities, the reader will be presented with an expert perspective on oncology therapeutics, drug development, and commercial opportunities within the field. The introductory chapter is designed to provide a global perspective on the many facets of cancer that will affect the discovery, development and marketing of oncology pharmaceuticals over the next decade. Among the critical disease parameters are the global epidemiology of cancer, which includes current incidence, survival and mortality trends for the most common cancers worldwide. This assessment is designed to focus attention on the types of cancer that may be most appropriately targeted for treatment research and development based on these current global statistics.

These statistics also highlight the types of cancer that continue to be most refractory to current treatment approaches, suggesting areas for future research in drug discovery. Each of the many common cancers is assessed in this chapter with respect to its aetiology, pathophysiology, diagnosis, current treatment options, and clinical outcomes.

Objectives of the Report
The objectives of this report are to provide an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, pipeline programs, and innovating companies and products. It is hoped that the reader will benefit from critical review, market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Contents List
List of Tables
List of Figures
List of Abbreviations
Executive Summary
Objective of the Report
Research Methodology

Chapter 1. Introduction to Cancer: Epidemiology, Pathophysiology, Diagnosis, and Treatment

Cancer Epidemiology
Global Epidemiology of Cancer
Global Statistics (World Health Organization - WHO)
Cancer Incidence and Mortality by Geographical Regions Worldwide
Cancer Epidemiology, United Kingdom (Office of National Statistics)
Cancer Incidence and Mortality
United Kingdom: Current Incidence Trends
Incidence by Age Group, United Kingdom
Current Mortality Trends in the United Kingdom
Survival Trends for Most Common Cancers in the United Kingdom
Current Cancer Statistics in the United States - American Cancer Society and
Surveillance, Epidemiology and End Results Program (SEER)
Current Incidence and Mortality Rates for the Most Common Cancers in the United
States
Current Cancer Estimates in the United States, 2005
Incidence and Mortality Rates by Racial Group, United States
Aetiology, Pathophysiology, and Diagnosis of Cancer by Type: Europe, United
Kingdom and United States
Lung Cancer
Aetiology of Lung Cancer
Risk Factors for Lung Cancer
Pathophysiology of Lung Cancer
Diagnosis of Lung Cancer
Treatment of Lung Cancer
Lung Cancer: Outcome
Colorectal Cancer
Aetiology and Pathophysiology
Risk Factors for Colon Cancer
Diagnosis of Colon Cancer
Treatment of Colon Cancer
Colon Cancer: Outcome
Breast Cancer
Aetiology of Breast Cancer
Risk Factors for Breast Cancer
Pathophysiology of Breast Cancer
Diagnosis of Breast Cancer
Treatment of Breast Cancer
Breast Cancer: Outcome
Prostate Cancer
Aetiology of Prostate Cancer
Pathophysiology of Prostate Cancer
Diagnosis of Prostate Cancer
Treatment of Prostate Cancer
Prostate Cancer: Outcome
Incidence and Mortality Rates for Other Common Cancers: Europe, and
North America
Cancer Staging and Grading: Diagnostic and Therapeutic Criteria
Common Solid Tumour Malignancies
Chemotherapy for Leukaemias and Lymphomas: Standard Treatment Options
Leukaemias
Lymphomas

Chapter 2. Drug Development Challenges

Tumour Biology
Important Discoveries in Tumour Biology: Viruses, Genes and Cancer
Cancer Genetics
Towards a Model on the Genetic Origins of Cancer
Pharmacology
Pharmacology of the Important Groups of Chemotherapeutic Drugs Used in the
Treatment of Cancer
Mechanism of Action of Major Groups Chemotherapy Drugs and Treatment Applications
Antimetabolites
Antibiotics
Alkylating Agents
Vinca Alkaloids
Other Alkaloids
Platinum Compounds
Treatment Resistance
General Parameters of Drug Resistance
Pharmacological Parameters of Chemosensitivity - Drug Delivery Applications
Genetic Components of Drug Resistance Mechanisms
Acquired Drug Resistance Mechanisms
Current Biological and Pharmacological Obstacles to the Successful Treatment
of Cancer
Biological Complexity
Pharmacological Challenges
New Research/Technologies
Gene-Targeted Therapeutic Approaches
Angiogenesis
Apoptosis
Application of New Technologies to Chemotherapy Research and Development

Chapter 3. Chemotherapeutic Treatment Options: Clinical Management and Drug Development Issues

Current Chemotherapies
Chemotherapy Treatment Overview
Treatment Options
Clinical Assessment of Solid Tumours
Organ-Specific Chemotherapy
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Testicular Cancer
Cancers of Haematopoetic Origin - The Leukaemias
Leukaemias
Hodgkin’s Disease
Non-Hodgkin’s Lymphoma
Chemotherapy Drugs Approved by the United States Food and Drug Administration
Chemotherapy Side Effects
Clinical Treatment Administration Protocols
Chemotherapy Drugs and Market Opportunities
Chemotherapy Drug Reformulation
Novel Drug Delivery Systems

Chapter 4. The Market for Cancer Chemotherapies

The Market for Chemotherapies
The Global Cancer Market: Trends, Estimates, Economics, and Outlook
Cancer Market: Overview
Best-Selling Oncology Products
Pharmaceutical Product Growth in Oncology
Licensing and Chemotherapy Products
Cancer Treatments and Pharmacoeconomics
Critical Factors Affecting the High Pricing o